Opinion: Getting past the bad blood of Theranos through collaboration
The Theranos saga comes with a silver lining — a recognition that liquid biopsies are going to take commitment and collaboration.
This week’s news that the Securities and Exchange Commission charged Theranos and with fraud put the troubles of the company back into the spotlight. For those of us in the field of liquid biopsy, Theranos has cast a long and persistent shadow on what’s clearly one of the most promising areas in cancer care — using blood tests to improve detection, diagnosis, and treatment and, more broadly, advancing the reality of precision medicine in cancer.
